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Abstract
As of 4 November, 2012, 100 patients with an acute muscular Sarcocystis-like illness associated 
with travel to Tioman Island, Malaysia, have been identified. Thirty-five travelled there mostly 
during July and August 2011 and 65 mostly during July and August 2012, suggesting an ongoing 
outbreak. Epidemiological investigations are ongoing. Public health agencies and practicing 
clinicians should be aware of this rarely-reported disease in humans and consider it as differential 
diagnosis in travellers returning from Tioman Island.
From 27 July to 4 November 2012, GeoSentinel [1], working with EuroTravNet [2] and 
TropNet [3], has identified 65 patients with an acute muscular Sarcocystis-like illness after 
recent travel to Tioman Island. All of these patients had traveled to Tioman, located off the 
east coast of peninsular Malaysia, mostly during July and August, 2012. Reports originated 
from Germany (n=25), France (n=20), the Netherlands (n=12), Switzerland (n=3), Belgium 
(n=2), Spain (n=2), and Singapore (n=1). These patients appear to represent the second wave 
of an outbreak that started in 2011 [4]. An epidemiologic investigation, initiated in 
November 2011, is ongoing.
Outbreak description
Starting from October 25, 2011, 35 patients with an acute muscular Sarcocystis-like illness 
were identified by early 2012; all traveled to Tioman Island, mostly during July and August 
of 2011. Following months without reports, new patients have been identified since late July 
2012, and 65 have been reported to GeoSentinel by 4 November 2012. Cases presented here 
with limited, preliminary data, are patients reported to GeoSentinel with suspected acute 
muscular sarcocystosis, defined as an acute illness characterised by prominent 
musculoskeletal complaints with or without fever, with unexplained eosinophilia and recent 
travel to Tioman Island.
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Although data collection is incomplete, the clinical presentation appears to be identical to 
that seen last year: almost all patients have experienced fever and myalgia while fewer have 
complained of arthralgia, asthenia, headache, cough, and diarrhoea. Only some had pruritic 
rash or edema of the face or an extremity. At least four patients were hospitalised.
Laboratory investigations showed that in many cases, at the onset of symptoms absolute 
eosinophil counts and serum creatinine phosphokinase (CPK) levels can be normal but begin 
to be moderately elevated approximately 30 days or more after departure from Tioman 
Island. Maximum absolute eosinophil counts and serum CPK levels from patients with data 
available, have typically been <1,000 cells/mm3 (norm: <500) and <1,500 U/L (norm: 
<200), respectively, but higher values were seen in some patients. To date, all patients with 
known testing (2011 n=34; 2012 n=8) have been serologically negative for trichinellosis. 
Eight patients are known to have had a muscle biopsy; for six patients results are available 
and all revealed myositis (defined as myalgia and inflammation and myocyte degeneration 
on histopathologic examination of muscle tissue) and in two intramuscular cysts (sarcocysts) 
were identified.
Among the 65 patients, two asymptomatic persons were identified who, when tested, had 
elevated eosinophil counts and serum CPK levels. One of them was a child who travelled 
with several family members, all of whom experienced an acute muscular Sarcocystis-like 
illness. The other person traveled with a companion who developed an acute muscular 
Sarcocystis-like illness and whose muscle biopsy showed inflammation but no intramuscular 
sarcocysts. The initially asymptomatic person subsequently developed myositis and mild 
myocarditis and was hospitalised.
Background
Sarcocystis species are intracellular protozoan parasites with an obligatory two-host 
predator-prey (definitive-intermediate) lifecycle [5]. Humans are the definitive host for 
Sarcocystis hominis and Sarcocystis suihominis, which are acquired by eating undercooked 
sarcocyst-containing beef or pork, respectively. The parasite reproduces sexually in the 
human intestine, where infection can cause acute gastroenteritis; however, most S. hominis 
and S. suihominis infections are likely asymptomatic [6]. Although the specific species have 
never been identified, humans can become accidental intermediate hosts for one or more of 
the 130 known Sarcocystis species through ingesting oocysts or sporocysts in food or water 
contaminated with feces from an infected predator animal. Nonspecific symptoms might 
arise during asexual reproductive and migratory phases of the parasite within the vascular 
endothelium and this generalised vasculitis has associated with myositis, myocarditis, and 
perivascular inflammation of the liver, kidneys, and lungs in experimentally and naturally 
infected animals [7]. The parasite ultimately disseminates to skeletal and cardiac muscle and 
forms sarcocysts containing large numbers of parasites that, when mature, are infectious for 
a definitive host. This phase in the lifecycle may or may not be associated with myocyte 
degeneration and active inflammation, depending on the specific Sarcocystis species-host 
species interaction [7]. Definitive diagnosis of muscular sarcocystosis relies on identifying 
sarcocysts in a muscle biopsy sample; DNA amplification and PCR testing of muscle tissue 
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and serology is experimental and not widely available. No proven treatment exists for 
human sarcocystosis.
Fewer than 100 cases of human muscular sarcocystosis have been reported in the literature, 
with most discovered incidentally in asymptomatic persons [6]. Human sarcocystosis is 
prevalent in Malaysia; a sero-prevalence study found evidence of infection in 20% of 243 
Malaysians [8] which is concordant with a 21% prevalence of sarcocysts found in muscle 
tissue from 100 consecutive autopsies in Malaysia [9]. The largest reported outbreak of 
apparent acute muscular disease in the past, affected seven of fifteen United States (US) 
servicemen on maneuvers in a Malaysian jungle [10]. All but one of them had symptoms, 
four had myositis and one was confirmed to have sarcocysts in his muscle.
Epidemiological investigation
GeoSentinel is coordinating an epidemiological investigation to systematically gather 
detailed demographic, travel, exposure, and clinical data using structured data collection 
instruments. Case finding activities have identified 100 persons with suspected Sarcocystis 
species after visiting Tioman Island, mostly during the 2011 and 2012 northern hemisphere 
summer tourist seasons.
A Sarcocystis-specific Western-blot serological assay is under development at the US 
Centers for Disease Control and Prevention (CDC) to assist in differentiating infected from 
non-infected persons associated with this outbreak. Histologic examination and DNA 
amplification is being performed at CDC on existing muscle biopsy specimens from 
outbreak patients to confirm the diagnosis of muscular sarcocystosis and to identify the 
responsible Sarcocystis species. Updates on the investigation are being provided to public 
health authorities in Malaysia and countries where patients have been identified.
Discussion and conclusion
This is the largest reported cluster of patients with suspected acute muscular sarcocystosis. 
With little known about this disease in humans, practicing clinicians’ awareness is likely 
low and many more as yet unrecognised patients may exist. Moreover, in agreement with a 
previously reported outbreak [10], our findings indicate that asymptomatic infection, and 
even late presentation, may occur. Since asymptomatic infection may be possible, the true 
number of persons infected by Sarcocystis species while visiting Tioman Island could be 
underestimated.
So far the data are still incomplete however, most patients analysed experienced acute 
illness characterised by fever and myositis. Myositis with significant eosinophilia but no 
serologic evidence of trichinellosis is an unusual clinical entity. Given the consistent pattern 
of illness among patients identified, the universal history of travel to a single small island in 
south-east Asia, and the presence of sarcocysts in the muscle biopsies of some of the 
patients, a Sarcocystis species infection with transmission occurring on Tioman Island 
seems to be the most likely cause of this outbreak. The source of infection for international 
travellers to Tioman Island remains unknown, but a seasonal pattern of transmission is 
apparent. This seasonality may reflect peak periods of summer tourist travel to the island, 
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but may also correlate with true seasonally-occurring contamination of food, water, or the 
environment, perhaps related to specific weather patterns, seasonal food sources, or other 
seasonal events.
The epidemiology of human muscular sarcocystosis in Malaysia and neighbouring countries 
is poorly investigated. Detailed ascertainment of risk behaviours and exposures associated 
with the current cluster of known cases is included in the survey instrument used for the 
investigation of the outbreak.
Travellers to Tioman Island should be made aware of this potential travel health risk and be 
reminded about the necessity to practice safe food and water consumption and proper 
hygiene. Public health officers and practicing clinicians who are aware of persons with 
prominent musculoskeletal complaints with or without fever, with unexplained eosinophilia 
and recent travel to Tioman Island, Malaysia, are encouraged to consider sarcocystosis as 
differential diagnosis. Moreover, they are invited to participate in our investigation and 
contact the corresponding author to report patients or receive guidance on how to proceed. 
Data collection forms and information on how to submit clinical samples (serum for 
Sarcocystis-specific serology and/or tissue for histopathology and Sarcocystis-specific PCR 
testing) are readily available.
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